These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30365949)

  • 21. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
    Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
    Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus.
    Sato Y; Suenaga T; Kobayashi M; Miyazaki N; Suzuki T; Ishioka K; Suzutani T
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0049421. PubMed ID: 34228537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Helicase-primase as a target of new therapies for herpes simplex virus infections.
    James SH; Larson KB; Acosta EP; Prichard MN
    Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High conservation of varicella-zoster virus helicase-primase complex, the target of the new antiviral drug amenamevir.
    Pacreau ML; Bomme O; Burrel S; Boutolleau D
    Antiviral Res; 2021 Nov; 195():105189. PubMed ID: 34666108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
    Biswas S; Jennens L; Field HJ
    Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
    Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
    J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Helicase primase: targeting the Achilles heel of herpes simplex viruses.
    Kleymann G
    Antivir Chem Chemother; 2004 May; 15(3):135-40. PubMed ID: 15266895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
    Takada A; Katashima M; Kaibara A; Sawamoto T; Zhang W; Keirns J
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):365-70. PubMed ID: 27129009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
    Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
    J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
    Biswas S; Swift M; Field HJ
    Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effect of amenamevir on acute herpetic pain and postherpetic neuralgia in mice infected with herpes simplex virus-1.
    Ueda Y; Uta D; Tanbo S; Kawabata A; Kanayama S; Osaki M; Nozawa N; Matsumoto T; Andoh T
    J Dermatol Sci; 2020 Apr; 98(1):50-57. PubMed ID: 32284168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment.
    Shiraki K; Takemoto M; Daikoku T
    Expert Rev Anti Infect Ther; 2021 Nov; 19(11):1415-1425. PubMed ID: 33853490
    [No Abstract]   [Full Text] [Related]  

  • 33. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
    Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
    Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
    Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection.
    Kaufman HE; Varnell ED; Gebhardt BM; Thompson HW; Atwal E; Rübsamen-Waigmann H; Kleymann G
    J Ocul Pharmacol Ther; 2008 Feb; 24(1):34-42. PubMed ID: 18201137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant.
    Sukla S; Biswas S; Birkmann A; Lischka P; Ruebsamen-Schaeff H; Zimmermann H; Field HJ
    Antiviral Res; 2010 Jul; 87(1):67-73. PubMed ID: 20420855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037.
    Gege C; Kleymann G
    Expert Opin Ther Pat; 2022 Sep; 32(9):933-937. PubMed ID: 35965439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1.
    Greeley ZW; Giannasca NJ; Porter MJ; Margulies BJ
    Antiviral Res; 2020 Apr; 176():104754. PubMed ID: 32114034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
    Wozniak MA; Frost AL; Itzhaki RF
    Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacological profiles and clinical effects of amenamevir tablet as treatments for herpes zoster].
    Maeda H; Nakamura H; Kikukawa Y
    Nihon Yakurigaku Zasshi; 2019; 153(1):35-43. PubMed ID: 30643090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.